F. Bosch / S. Erill
Modern clinical researchers, and in particular those involved in clinical trials, are completely knowledgeable with the concepts of comparators, double blind, randomization, placebos, statistical analysis and many others that have become almost common words in everyday language. However, probably not all of them have had the opportunity to assist, through the relevant references, to the birth of many of these terms or, at least, to the precise and definite use of them by the clinical investigators who, among other feats, shaped the field of clinical pharmacology.
In the Pharmacotherapy Revisited number 7 we pretend to revisit those papers that, in one way or another, have attracted our attention as landmarks in the development of clinical pharmacology. The results achieved in some of them are probably of little interest today, but what we want to honor is the methodological advances they provided at the time they were published. Thus, we still marvel at the quality of the research achieved by Harry Gold with the simple use of the stethoscope to record the heart rate, and celebrate the quality of the MRC trials and insights of Austin Bradford Hill. We also marvel at the work of Beecher’s group, measuring subjective responses, which was to be the cradle of the impressive figure of Louis Lasagna.
The role of the Geigy pharmaceutical company in fostering drug kinetics is very seldom acknowledged, but those who may believe that many of the nuts and bolts of the issue are of quite recent design should perhaps consider the 1953 paper of Burns et al. (among them the outstanding figure of BB Brodie) on phenylbutazone. On the other hand, the need to pay attention to the problem of transposition of drug studies from laboratory to clinic was also explicit in 1960.
The development of clinical pharmacology, a term coined by Gold in 1952, needed refinements and also attention to practical issues. Many contributed, but we still read with pleasure the inputs of Laurence, Wolf and Carr, which highlight once more the pivotal role of British and American authors in the early years of this discipline.
Finally, we would like to comment on the inclusion of two papers, one (of 1959!) showing that the effect of drugs on athletic performance can be rigorously measured and that not all people benefit even from those proven to work. The other, a Book Review published in 1969, provides what is for us the ultimate proof of the need of the double-blind technique. Interestingly enough, the hero of the story is a horse!
Let us end with a note on the pleasure that we derived from reading these articles when we were initially exposed to them and now in preparing this subjective selection. We sincerely hope that you may share this pleasure.
F. Bosch & S. Erill
|Full PDF||F. Bosch / S. Erill||[wpdm type=”btn3″]|
|Acknowledgements||[wpdm id=31 type=”btn”]|
|Introduction||F. Bosch / S. Erill||[wpdm id=32 type=”btn”]|
|Index||[wpdm id=31 type=”btn”]|
|1. A clinical trial of sanocrysin in pulmonary tuberculosis||JB Amberson Jr / BT McMahon / M Pinner||[wpdm type=”btn3″]|
|2. The comparative value of drugs used in the continuous treatment of angina pectoris||W Evans / C Hoyle||[wpdm type=”btn3″]|
|3. The xanthines (theobromine and aminophylline) in the treatment of cardiac pain||H Gold / NT Kwit / H Otto||[wpdm type=”btn3″]|
|4. A method for the bio-assay of digitalis in humans||H Gold / M Cattell / HL Otto / NT Kwit / ML Kramer||[wpdm type=”btn3″]|
|5. Clinical trial of patulin in the common cold||MCR Patulin Clinical Trials Committee||[wpdm type=”btn3″]|
|6. Streptomycin treatment of pulmonary tuberculosis||MRC Streptomycin in Tuberculosis Trials Committee||[wpdm type=”btn3″]|
|7. A method for the evaluation of the effects of drugs on cardiac pain in patients with angina of effort: a study of khellin (visammin)||T Greiner / H Gold / M Cattell et al.||[wpdm type=”btn3″]|
|8. Measurement of pathological pain in distinction to experimental pain||AS Keats / HK Beecher / FC Mosteller||[wpdm type=”btn3″]|
|9. The role of dual reading in mass radiography||J Yerushalmy / JT Harkness / JH Cope / BR Kennedy||[wpdm type=”btn3″]|
|10. The clinical trial||AB Hill||[wpdm type=”btn3″]|
|11. Experimental pharmacology and measurement of the subjective response||HK Beecher||[wpdm type=”btn3″]|
|12. “The proper study of mankind is the man.”||H Gold||[wpdm type=”btn3″]|
|13. The physiological disposition of phenylbutazone (Butazolidin) in man and a method for its estimation in biological material||JJ Burns / RK Rose / T Chenkin / A Goldman / A Schulert / BB Brodie||[wpdm type=”btn3″]|
|14. Lind, lemons and limeys||SO Waife||[wpdm type=”btn3″]|
|15. How to evaluate a new drug||Conference on Therapy||[wpdm type=”btn3″]|
|16. Clinical pharmacology||JH Gaddum||[wpdm type=”btn3″]|
|17. The optimal dose of morphine||L Lasagna / HK Beecher||[wpdm type=”btn3″]|
|18. The powerful placebo||HK Beecher||[wpdm type=”btn3″]|
|19. Measurement in medicine||M Hamilton||[wpdm type=”btn3″]|
|20. Factors influencing clinical evaluation of drugs with special reference to the double-blind technique||W Modell / RW Houde||[wpdm type=”btn3″]|
|21. Amphetamine sulfate and athletic performance. I. Objective effects||GM Smith / HK Beecher||[wpdm type=”btn3″]|
|22. Transposition of drug studies from laboratory to clinic||KH Beyer||[wpdm type=”btn3″]|
|23. Some fallacies and errors in the application of the principle of consent in human experimentation||HK Beecher||[wpdm type=”btn3″]|
|24. Part VI. Difficulties in extrapolating data on metabolism of drugs from animals to man||BB Brodie||[wpdm type=”btn3″]|
|25. Patient selection and stratification in therapeutic trials||DR Laurence||[wpdm type=”btn3″]|
|26. Part IV. Placebos: Problems and pitfalls||S Wolf||[wpdm type=”btn3″]|
|27. Heberden Oration, 1965: Reflections on the controlled trial||AB Hill||[wpdm type=”btn3″]|
|28. Practical considerations in the design of clinical trials||EA Carr Jr||[wpdm type=”btn3″]|
|29. Clever Hans: The horse of Mr. Von Osten||W Modell||[wpdm type=”btn3″]|
|30. The role of randomization in clinical trials||P Armitage||[wpdm type=”btn3″]|
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information. Les cookies necessàries són absolutament essencials perquè el lloc web funcioni correctament. Aquesta categoria només inclou galetes que garanteixen funcionalitats bàsiques i funcions de seguretat del lloc web. Aquestes cookies no emmagatzemen cap informació personal. Las cookies necesarias son absolutamente esenciales para que el sitio web funcione correctamente. Esta categoría solo incluye cookies que garantizan funcionalidades básicas y características de seguridad del sitio web. Estas cookies no almacenan ninguna información personal.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website. Totes les galetes que poden no ser especialment necessàries perquè el lloc web funcioni i s’utilitzen específicament per recopilar dades personals de l’usuari mitjançant analítiques, anuncis i altres continguts incrustats s’anomenen cookies no necessàries. És obligatori obtenir el consentiment de l'usuari abans d'executar aquestes cookies al vostre lloc web. Las cookies que pueden no ser particularmente necesarias para el funcionamiento del sitio web y que se utilizan específicamente para recopilar datos personales del usuario a través de análisis, anuncios y otros contenidos integrados se denominan cookies no necesarias. Es obligatorio obtener el consentimiento del usuario antes de ejecutar estas cookies en su sitio web.